Platelet derived growth factor expression, myelofibrosis and chronic myelogenous leukemia

• Published in: Leukemia & lymphoma Vol. 18; no. 3-4; p. 237
• Main Authors: Kimura, A, Katoh, O, Hyodo, H, Kuramoto, A, Satow, Y
• Format: Journal Article
• Language: English
• Published: United States 1995
• Subjects: Blast Crisis; Fibroblasts - metabolism; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology; Platelet-Derived Growth Factor - biosynthesis; Primary Myelofibrosis - metabolism
• ISSN: 1042-8194
• DOI: 10.3109/10428199509059613

CML is often associated with myelofibrosis, and fibrosis in the accelerated phase is one of the diagnostic criteria for this accelerated phase. In this review, the mechanism of myelofibrosis associated with CML is discussed with emphasis on the cell origin of the production and release of platelet derived growth factor (PDGF) and its interaction with marrow fibroblasts. In the initial stage of myelofibrosis in chronic phase CML, atypical small megakaryocytes might leak PDGF, possibly PDGF-AB, together with other growth factors. As the clinical phase of the disease progresses to accelerated or blastic phase, a larger quantity of PDGF-AB or PDGF-BB might be secreted from blastic cells with myeloid phenotype. In addition some fibroblasts may be attracted by the PDGF and proliferate, and deposit collagen as well as fibronectin in the bone marrow stroma.